MDXG MiMedx Group Inc.

MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum

MiMedx To Present At Canaccord Genuity Virtual MedTech & Diagnostics Forum

MARIETTA, Ga., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today announced that Timothy R. Wright, MiMedx Chief Executive Officer, and Peter M. Carlson, MiMedx Chief Financial Officer, will present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum on Thursday, November 19, 2020, beginning at 9:30 am, Eastern Time.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website or through the conference site by using the link below.

Date: Thursday, November 19, 2020

Time: 9:30 AM ET

Webcast:  

A replay of the webcast will be available for approximately 45 days on the Company’s website at following the conclusion of the presentation.

About MiMedx

MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied more than two million allografts, through both direct and consignment shipments. For additional information, please visit .

Contact

Hilary Dixon

Investor Relations & Corporate Communications

770.651.9066

 

EN
12/11/2020

Underlying

MDXGMiMedx Group Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Sponsor Leading Advanced Wound Care Conferences

MIMEDX to Sponsor Leading Advanced Wound Care Conferences Multispecialty Focus with Industry Leadership Aimed at Improving Patient Outcomes Company Will Feature Recent Additions to Its Advanced Wound Care Portfolio MARIETTA, Ga., April 02, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its participation in two leading wound care conferences: the Symposium on Advanced Wound Care (“SAWC”) Spring 2026 and MedStar Georgetown University Hospital’s Diabetic Limb Salvage (“DLS”) Conference. Through scientific presentations, clinician edu...

April 2, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Launch of CHORIOFIX™

MIMEDX Announces Launch of CHORIOFIX™ Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products MARIETTA, Ga., March 23, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of CHORIOFIX™, the latest advanced wound care innovation in its product portfolio of placental allografts. “CHORIOFIX is an organically developed product, created based on our deep understanding of the scientific and clinical attributes of the chorion layer,” stated Michelle Massee, MIMEDX VP, Research & Development. “It...

March 23, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX®...

MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX® Thyroid Shields Bolsters Surgical offering with product specifically designed for use in endocrine procedures MARIETTA, Ga., March 05, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of AMNIOFIX Thyroid Shields, a product line extension of the Company’s AMNIOFIX dehydrated human amnion/chorion membrane (DHACM) allografts. AMNIOFIX Thyroid Shields are allografts designed and intended for use in endocrine surgery. Following a thyroidectomy,...

March 5, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating an...

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results Net Sales Grew 27% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $15 million and $0.10, Respectively Fourth Quarter Adjusted EBITDA1 was $29 Million, or 25% of Net Sales Company Estimates 2026 Net Sales in a Range of $340-360 Million Announces $100 Million Share Repurchase Program Authorization Management to Host Conference Call Today, February 25, 2026, at 4:30 PM ET MARIETTA, Ga., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Mi...

February 25, 2026 1 EN
 PRESS RELEASE
Free
MDXG MiMedx Group I...

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financi...

MIMEDX to Host Fourth Quarter and Full Year 2025 Operating and Financial Results Conference Call on February 25 MARIETTA, Ga., Feb. 17, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, February 25, 2026. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be access...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch